Corydaline

Corydaline is a protoberberine alkaloid (molecular weight 369.44 g/mol) that exerts anti-inflammatory activity by inhibiting LPS-induced inflammatory signaling in macrophages, with putative involvement of NF-κB pathway suppression inferred from related alkaloid research. In vitro studies in RAW 264.7 macrophage cells demonstrate that corydaline suppresses inflammation at 10–60 µM concentrations without cytotoxicity up to 90 µM, though no human clinical trial data currently support efficacy claims for isolated corydaline.

Origin & History

Corydaline is a protoberberine isoquinoline alkaloid isolated from the rhizomes of Corydalis yanhusuo (Yan Hu Suo), a flowering plant native to northeastern China, Siberia, and Japan, cultivated primarily in Zhejiang, Jiangsu, and Hunan provinces of China. The plant thrives in moist, shaded woodland environments and is harvested in late spring when rhizomes reach maturity. Corydaline co-occurs with over 100 other alkaloids in C. yanhusuo, where it constitutes approximately 0.83 mg per gram of plant extract alongside dehydrocorydaline, tetrahydropalmatine, and berberine.

Historical & Cultural Context

Corydalis yanhusuo (Yan Hu Suo, 延胡索) has been employed in Traditional Chinese Medicine (TCM) for over 1,500 years, with documentation in the Tang Materia Medica (Bencao Shiyi, 8th century CE) and the Compendium of Materia Medica (Bencao Gangmu, 1596 CE) by Li Shizhen, who described the rhizome as effective for invigorating blood circulation and relieving pain. The rhizome was traditionally prepared by steaming, vinegar-processing (cu zhi), or decocting, with vinegar processing (soaking in rice vinegar before drying) believed to enhance alkaloid extraction and analgesic potency — a practice now understood to increase solubility of alkaloids as acetate salts. Corydaline as a discrete chemical entity was first isolated and characterized in the 20th century alongside the structural elucidation of other C. yanhusuo protoberberine alkaloids, transitioning the traditional botanical from a holistic decoction to a source of pharmacologically defined compounds for mechanistic research. The broader Corydalis genus, encompassing over 400 species distributed across temperate Asia and Europe, holds significant ethnopharmacological relevance in Tibetan, Korean, and Japanese herbal medicine traditions as well.

Health Benefits

- **Anti-Inflammatory Activity**: Corydaline inhibits LPS-induced inflammatory responses in RAW 264.7 macrophages at 10–60 µM, exhibiting lower potency but substantially greater cellular safety than its structural analog dehydrocorydaline, which becomes cytotoxic above 20 µM.
- **Preclinical Analgesic Potential**: As a component of Corydalis yanhusuo, corydaline contributes to the plant's long-established analgesic profile in traditional Chinese medicine; its protoberberine scaffold is associated with modulation of pain-relevant neurotransmitter systems in animal models.
- **Favorable In Vitro Safety Window**: Unlike several co-occurring alkaloids in C. yanhusuo, corydaline demonstrates no cytotoxicity in macrophage cultures at concentrations up to 90 µM (~33 µg/mL), suggesting a broader therapeutic index in cellular systems, though this has not been confirmed in vivo.
- **Tissue Bioavailability in Animal Models**: Pharmacokinetic studies using transdermal delivery of total C. yanhusuo alkaloids in rats confirmed detection of corydaline in plasma, heart, liver, spleen, lung, and kidney via UPLC-MS/MS, indicating systemic absorption and multi-organ distribution.
- **Contribution to Multi-Alkaloid Synergy**: Within whole C. yanhusuo extracts, corydaline functions as one of several bioactive protoberberine alkaloids; its combined presence with dehydrocorydaline (1.80 mg/g), glaucine (1.39 mg/g), and tetrahydropalmatine is thought to contribute to the extract's aggregate pharmacological activity.
- **Research Tool Compound**: High-purity corydaline (≥98%) is commercially available as a research chemical soluble in DMSO at ≥18.13 mg/mL, enabling mechanistic dissection of individual alkaloid contributions to C. yanhusuo's biological effects in preclinical screening paradigms.

How It Works

Corydaline belongs to the protoberberine class of isoquinoline alkaloids, sharing a tetracyclic ring system that confers affinity for multiple biological targets including dopamine, serotonin, and opioid receptors — a receptor profile established for structurally related C. yanhusuo alkaloids such as l-tetrahydropalmatine. In RAW 264.7 macrophage models, corydaline at 10–60 µM suppresses LPS-triggered inflammatory mediator production, with mechanistic inference from extract-level studies pointing toward inhibition of the NF-κB transcription factor pathway, which governs expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. The compound's specific binding targets — including potential interactions with D1/D2 dopamine receptors, μ-opioid receptors, or TRPV1 channels — have not been individually characterized in published peer-reviewed literature as of the available evidence base. Its greater cellular safety margin relative to dehydrocorydaline (cytotoxicity threshold >90 µM vs. ~20 µM) may reflect differences in quinolinium ion formation potential between the two structural analogs.

Scientific Research

The current evidence base for isolated corydaline consists exclusively of in vitro cell culture studies and animal pharmacokinetic experiments; no human clinical trials evaluating isolated corydaline as a standalone intervention have been published. Anti-inflammatory activity has been characterized in LPS-stimulated RAW 264.7 murine macrophages at concentrations of 10–60 µM, with corydaline demonstrating statistically significant but comparatively modest inhibition relative to co-alkaloid dehydrocorydaline. Pharmacokinetic biodistribution data derive from rat studies using transdermal patch delivery of total C. yanhusuo alkaloids quantified by UPLC-MS/MS on an ACQUITY HSS T3 column, confirming systemic absorption but providing no human bioavailability estimates. The broader clinical literature for C. yanhusuo extract supports analgesic applications, but attribution of specific effects to corydaline versus co-occurring alkaloids such as l-tetrahydropalmatine or dehydrocorydaline remains methodologically unresolved.

Clinical Summary

No randomized controlled trials, observational studies, or pharmacokinetic studies in human subjects specifically evaluating isolated corydaline have been identified in the peer-reviewed literature. Clinical analgesic and anti-inflammatory evidence pertaining to Corydalis yanhusuo as a botanical is extrapolated from traditional use validation studies and extract-level investigations, not from trials isolating corydaline's individual contribution. The compound's quantified concentration in commercial C. yanhusuo products ranges from below the limit of quantification to approximately 11 mg/g total alkaloids (HPLC-UV at 205 nm, LOQ 5–6 ng/injection), highlighting substantial inter-product variability that complicates dose-response extrapolation. Confidence in clinical benefit attributable specifically to corydaline must be rated as very low pending dedicated human pharmacokinetic and efficacy trials.

Nutritional Profile

Corydaline is a pure alkaloid compound (C21H25NO4, MW 369.44 g/mol) and does not contribute macronutrients, vitamins, or dietary minerals. Its pharmacological relevance is entirely phytochemical: as a protoberberine-class isoquinoline alkaloid, its bioactivity derives from its tetracyclic nitrogen-containing ring structure. Within C. yanhusuo rhizome, corydaline is present at approximately 0.83 mg/g dry extract weight; it co-occurs with dehydrocorydaline (~1.80 mg/g), glaucine (~1.39 mg/g), coptisine (~0.65 mg/g), rotundine (~0.56 mg/g), columbamine (~0.46 mg/g), palmatine (~0.43 mg/g), and berberine (~0.10 mg/g). Bioavailability of corydaline from oral or transdermal administration has been confirmed in rat tissues by UPLC-MS/MS but has not been quantified as an absolute oral bioavailability fraction; DMSO solubility (≥18.13 mg/mL) and aqueous insolubility suggest formulation-dependent absorption limitations in biological systems.

Preparation & Dosage

- **Research-Grade Powder**: Available as isolated compound (≥98% purity) for laboratory use; soluble in DMSO at ≥18.13 mg/mL with ultrasonic assistance; not water- or ethanol-soluble at practical concentrations.
- **In Vitro Reference Concentrations**: Cell-based studies have used 10–60 µM (~3.7–22.2 µg/mL based on MW 369.44 g/mol); these concentrations are not translatable to clinical dosing without pharmacokinetic bridging data.
- **Whole-Extract Context**: In commercial C. yanhusuo products, corydaline contributes approximately 0.83 mg/g of total alkaloid content; typical traditional dried rhizome doses of C. yanhusuo range from 3–9 g/day in decoction form, implying incidental corydaline intake of approximately 2.5–7.5 mg/day from this source.
- **Transdermal Delivery (Animal Model)**: Rat studies employed acupoint (Shenque) transdermal patches loaded with total alkaloids including corydaline; no human transdermal dose has been validated.
- **Standardized Supplements**: No internationally recognized standardization specification for corydaline content exists; C. yanhusuo supplements are more commonly standardized to total alkaloids or to tetrahydropalmatine content.
- **Storage**: Isolated corydaline solid should be stored at −20°C, protected from moisture and light, to maintain chemical integrity.

Synergy & Pairings

Within C. yanhusuo extracts, corydaline is presumed to act synergistically with l-tetrahydropalmatine (rotundine) and dehydrocorydaline, with the former contributing D1/D2 dopamine receptor antagonism and putative opioid receptor modulation, and the latter contributing more potent NF-κB-mediated anti-inflammatory effects — together producing a broader analgesic and anti-inflammatory profile than any single alkaloid in isolation. The traditional TCM vinegar-processing (cu zhi) of C. yanhusuo rhizome may enhance corydaline's bioavailability by converting the free base to its acetate salt form, improving aqueous solubility and potentially facilitating co-absorption of multiple alkaloids simultaneously. Corydaline has not been evaluated in combination with exogenous analgesic agents (e.g., NSAIDs, opioids, or cannabinoids) in published preclinical or clinical studies, and such pairings cannot be recommended based on available evidence.

Safety & Interactions

In vitro cytotoxicity data from RAW 264.7 murine macrophages show no cellular toxicity at concentrations up to 90 µM (~33 µg/mL), providing a favorable initial safety signal; however, in vivo toxicity studies and human safety data for isolated corydaline are absent from the published literature, making definitive safety characterization impossible at this time. Drug interaction data specific to corydaline do not exist in the clinical literature; extrapolation from structurally related protoberberine alkaloids (e.g., berberine, tetrahydropalmatine) raises theoretical concerns about interactions with CYP450 enzymes (particularly CYP2D6 and CYP3A4), drugs metabolized via monoamine pathways, and central nervous system depressants given the alkaloid class's receptor pharmacology. No contraindications, pregnancy safety data, or lactation guidance exist for isolated corydaline; use during pregnancy and lactation should be avoided in the absence of safety evidence, consistent with the precautionary principle applied to poorly characterized alkaloids. The significant variability in corydaline content across commercial C. yanhusuo products (from undetectable to ~11 mg/g total alkaloids) presents an additional safety concern related to unintentional dose escalation when using standardized extracts.